Press Releases Ypsomed Group

Burgdorf – Starting in the US from September 2014, the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide will be administered with the dual-chamber injection system Bydureon Pen, based on Ypsomed's LyoTwist® platform.

Press Releases Ypsomed Group

Burgdorf – Annual general meeting of July 1, 2014.

Press Releases Ypsomed Group

Burgdorf – Injection Systems and Diabetes Care to be managed separately.

Press Releases Ypsomed Group

Burgdorf – Ypsomed successfully implements turnaround strategy and signs three new Injection Systems contracts with GlaxoSmithKline (GSK), Palatin Technologies, Inc. and Pharmstandard.

Press Releases Ypsomed Group

Burgdorf – Simon Michel elected as successor of CEO Willy Michel.